Drug Profile

Opelconazole - Pulmocide

Alternative Names: PC-945

Latest Information Update: 14 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pulmocide
Class Antifungals; Benzamides; Fluorobenzenes; Oxalates; Phenyl ethers; Piperazines; Small molecules; Triazoles
Mechanism of Action 14-alpha demethylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Aspergillosis
New Molecular Entity Yes

Highest Development Phases

Phase III Aspergillosis
Phase II Candidiasis

Most Recent Events

13 Jan 2025 Opelconazole - Pulmocide receives Orphan Drug status for Aspergillosis in European Union
15 Apr 2024 Efficacy and adverse events data from the phase II OPERA-S trial in Aspergillosis were released by Pulmocide
13 Nov 2023 Pulmocide completes a phase II trial in Aspergillosis (Monotherapy) in the USA and Canada (Inhalation) (NCT05037851)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com